Skip to main content
Premium Trial:

Request an Annual Quote

Edge BioSystems Licenses Protein-Refolding Technology from KU Medical Center

NEW YORK, April 20 (GenomeWeb News) - Kansas University Medical Center has given Edge BioSystems a license to manufacture and use a protein-refolding technology that Edge plans to apply to drug discovery and diagnostics, the organizations said today.


Edge sees a "very broad range of applications for this technology," including large-scale functional assays for drug discovery, target validation, high-throughput screening, and possibly structural studies, Omayma Al-Awar, director of sales and marketing for Edge, told GenomeWeb News today. The company believes the technology will be useful to customers in academia and pharmaceutical companies, she added.


Al-Awar declined to disclose financial terms of the license.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.